Zhao-Yu Liu1, Zhi-Hui Chang, Zai-Ming Lu, Qi-Yong Guo. 1. Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China. liuzy@sj-hospital.org
Abstract
BACKGROUND: Morphologic imaging after radiofrequency ablation (RFA) of liver metastases is hampered by an inflammatory response in the ablation margin, making the identification of local tumor progression (LTP) difficult. The aim of this study was to evaluate the efficacy of early (18)F-FDG PET/CT scanning to monitor the effectiveness of RFA in colorectal liver metastases. METHODS: Twelve patients with 20 metastases were treated with RFA for colorectal liver metastases. They underwent PET/CT within 2 weeks before RFA and within 24 hours after RFA (so termed "early PET/CT"). PET/CT was repeated at 1, 3, and 6 months, and then every 6 months after ablation. The standard of reference was based on available clinical and radiological follow-up data. RESULTS: Early PET/CT revealed total photopenia in 16 RFA-treated metastases, which were found to be without residual tumor on the final PET/CT scan. Three RFA-treated metastases with focal uptake were identified as local tumor progression, which necessitated further treatment. One RFA-treated metastasis with rim-shaped uptake was regarded as inflammation. The results of the early PET/CT scanning were consistent with the findings of the final follow-up. CONCLUSIONS: PET/CT performed within 24 hours after RFA can effectively detect whether residual tumor exists for colorectal cancer liver metastases. The results can guide further treatment, and may improve the efficacy of RFA.
BACKGROUND: Morphologic imaging after radiofrequency ablation (RFA) of liver metastases is hampered by an inflammatory response in the ablation margin, making the identification of local tumor progression (LTP) difficult. The aim of this study was to evaluate the efficacy of early (18)F-FDG PET/CT scanning to monitor the effectiveness of RFA in colorectal liver metastases. METHODS: Twelve patients with 20 metastases were treated with RFA for colorectal liver metastases. They underwent PET/CT within 2 weeks before RFA and within 24 hours after RFA (so termed "early PET/CT"). PET/CT was repeated at 1, 3, and 6 months, and then every 6 months after ablation. The standard of reference was based on available clinical and radiological follow-up data. RESULTS: Early PET/CT revealed total photopenia in 16 RFA-treated metastases, which were found to be without residual tumor on the final PET/CT scan. Three RFA-treated metastases with focal uptake were identified as local tumor progression, which necessitated further treatment. One RFA-treated metastasis with rim-shaped uptake was regarded as inflammation. The results of the early PET/CT scanning were consistent with the findings of the final follow-up. CONCLUSIONS: PET/CT performed within 24 hours after RFA can effectively detect whether residual tumor exists for colorectal cancer liver metastases. The results can guide further treatment, and may improve the efficacy of RFA.
Authors: Don C Yoo; Damian E Dupuy; Shauna L Hillman; Hiran C Fernando; William S Rilling; Jo-Anne O Shepard; Barry A Siegel Journal: AJR Am J Roentgenol Date: 2011-08 Impact factor: 3.959
Authors: E Ronan Ryan; Constantinos T Sofocleous; Heiko Schöder; Jorge A Carrasquillo; Sadek Nehmeh; Steven M Larson; Raymond Thornton; Robert H Siegelbaum; Joseph P Erinjeri; Stephen B Solomon Journal: Radiology Date: 2013-04-05 Impact factor: 11.105
Authors: Juliana Romanato; Marcos Roberto Menezes; Allan de Oliveira Santos; Regis Otaviano Franca Bezerra; Mariana Cunha Lopes Lima; Elba Etchebehere Journal: Radiol Bras Date: 2019 Jan-Feb
Authors: Okker D Bijlstra; Maud M E Boreel; Sietse van Mossel; Mark C Burgmans; Ellen H W Kapiteijn; Daniela E Oprea-Lager; Daphne D D Rietbergen; Floris H P van Velden; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; J Sven D Mieog; Lioe-Fee de Geus-Oei Journal: Diagnostics (Basel) Date: 2022-03-15